TE-8105

TE-8105 is an ultralong-acting human glucagon-like peptide 1 receptor (GLP-1R) agonist peptide, designed as a modified segment (#7–37) of native human GLP-1. It features two key modifications for enhanced pharmacokinetics and efficacy: alanine at position 8 is replaced by 2-aminoisobutyric acid, and lysine at position 26 is conjugated with a fatty acid bundle containing both a C16 acid and a C18 diacid. These modifications increase albumin binding, prolong half-life, and improve glucose-lowering effects compared to semaglutide in preclinical models. TE-8105 stimulates glucose-dependent insulin secretion, retards glucagon-like peptide 1 receptor internalization for sustained activation, and has demonstrated superior efficacy in reducing blood glucose levels and body weight in animal models of type 2 diabetes (T2D), obesity, and nonalcoholic steatohepatitis (NASH/MASH). The drug is administered subcutaneously. TE-8105 is being developed by Immunwork for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NASH)[1][2][4][5].